Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Clinical Trials

PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]

Not Applicable

Not yet recruiting

Conditions: Preterm Birth

Interventions: Drug: Erythromycin
Drug: Amoxicillin and Erythromycin
Drug: Azithromycin

First Posted Date: 2024-06-17

Last Posted Date: 2024-06-17

Lead Sponsor: University of Melbourne

Target Recruit Count: 100000

Registration Number: NCT06461429

Effect of Saccharomyces Boulardii CNCM I-745 on Gut Microbiota in Patients Undergoing Antibiotic Therapy (in the Context of Erythema Migrans (early Skin Form of Lyme Borreliosis))

Phase 4

Not yet recruiting

Conditions: Erythema Migrans of Lyme Disease

Interventions: Drug: Amoxicillin + Saccharomyces boulardii CNCM I-745
Drug: Amoxicillin + Placebo
Other: Stool samples

First Posted Date: 2024-06-11

Last Posted Date: 2025-02-06

Lead Sponsor: Biocodex

Target Recruit Count: 120

Registration Number: NCT06451913

Comparison of Twice- and Four-times-daily Amoxicillin Administration in 2-week Tegoprazan-based H. Pylori Eradication

Completed

Conditions: H.Pylori Infection

Interventions: Drug: Amoxicillin

First Posted Date: 2024-05-29

Last Posted Date: 2025-04-30

Lead Sponsor: Soonchunhyang University Hospital

Target Recruit Count: 100

Registration Number: NCT06431737

Locations: 🇰🇷
Soonchunhyang University Hospital, Seoul, Korea, Republic of

Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori

Phase 3

Completed

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Vonoprazan, Amoxicillin and Levofloxacin
Drug: Pantoprazole 40mg, Amoxicillin and Levofloxacin

First Posted Date: 2024-05-16

Last Posted Date: 2024-05-16

Lead Sponsor: Ain Shams University

Target Recruit Count: 320

Registration Number: NCT06414707

Locations: 🇪🇬
Mostafa Elfors, Cairo, Egypt

Optimization of Keverprazan-amoxicilli Dual Therapy for Helicobacter Pylori

Phase 4

Not yet recruiting

Conditions: H. Pylori Infection

Interventions: Drug: Keverprazan
Drug: Amoxicillin

First Posted Date: 2024-05-14

Last Posted Date: 2024-05-14

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 268

Registration Number: NCT06412640

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Phase 2

Recruiting

Conditions: Drug Allergy
Cephalosporin Allergy
Drug Hypersensitivity
Antibiotic Allergy
Beta Lactam Adverse Reaction
Drug-Induced Anaphylaxis
Cephalosporin Reaction

Interventions: Drug: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing
Drug: Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge
Drug: Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge
Drug: Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge
Drug: Amoxicillin double-blind placebo-controlled drug challenge

First Posted Date: 2024-05-09

Last Posted Date: 2025-05-06

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 300

Registration Number: NCT06406114

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 3 locations